BRPI0409787B8 - antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a - Google Patents

antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a

Info

Publication number
BRPI0409787B8
BRPI0409787B8 BRPI0409787A BRPI0409787B8 BR PI0409787 B8 BRPI0409787 B8 BR PI0409787B8 BR PI0409787 A BRPI0409787 A BR PI0409787A BR PI0409787 B8 BRPI0409787 B8 BR PI0409787B8
Authority
BR
Brazil
Prior art keywords
triazol
pyrazol
alkynyl
alkenyl
receptor antagonists
Prior art date
Application number
Other languages
English (en)
Inventor
Stamford Andrew
R Neustadt Bernard
D Boyle Craig
Liu Hong
Hao Jinsong
Chackalamannil Samuel
G Shah Unmesh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BRPI0409787A publication Critical patent/BRPI0409787A/pt
Publication of BRPI0409787B1 publication Critical patent/BRPI0409787B1/pt
Publication of BRPI0409787B8 publication Critical patent/BRPI0409787B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0409787-4 2003-04-23 2004-04-21 antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a BRPI0409787B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46484003P 2003-04-23 2003-04-23
US60/464,840 2003-04-23
PCT/US2004/012471 WO2004094431A2 (en) 2003-04-23 2004-04-21 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0409787A BRPI0409787A (pt) 2006-05-30
BRPI0409787B1 BRPI0409787B1 (pt) 2018-08-21
BRPI0409787B8 true BRPI0409787B8 (pt) 2021-05-25

Family

ID=33310963

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409787-4 BRPI0409787B8 (pt) 2003-04-23 2004-04-21 antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a

Country Status (31)

Country Link
US (2) US6897217B2 (pt)
EP (1) EP1622912B1 (pt)
JP (2) JP4527712B2 (pt)
KR (1) KR100831107B1 (pt)
CN (1) CN100503609C (pt)
AR (1) AR044041A1 (pt)
AT (1) ATE432282T1 (pt)
AU (1) AU2004233334B2 (pt)
BR (1) BRPI0409787B8 (pt)
CA (1) CA2522813C (pt)
CL (1) CL2004000847A1 (pt)
CO (1) CO5700766A2 (pt)
CY (1) CY1109263T1 (pt)
DE (1) DE602004021250D1 (pt)
DK (1) DK1622912T3 (pt)
EC (1) ECSP056115A (pt)
ES (1) ES2326270T3 (pt)
HR (1) HRP20090394T1 (pt)
IL (1) IL171567A (pt)
MX (1) MXPA05011366A (pt)
MY (1) MY139344A (pt)
NO (1) NO332182B1 (pt)
NZ (1) NZ542823A (pt)
PE (1) PE20050141A1 (pt)
PL (2) PL378867A1 (pt)
PT (1) PT1622912E (pt)
RU (1) RU2373210C2 (pt)
SI (1) SI1622912T1 (pt)
TW (2) TWI375677B (pt)
WO (1) WO2004094431A2 (pt)
ZA (1) ZA200508489B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7313588B1 (en) * 2000-07-13 2007-12-25 Biap Systems, Inc. Locally executing software agent for retrieving remote content and method for creation and use of the agent
AU2002346503A1 (en) * 2001-11-30 2003-06-17 Schering Corporation Adenosine A2a receptor antagonists
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
MXPA05006790A (es) 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) * 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
JPWO2006132275A1 (ja) 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
AR057817A1 (es) * 2005-09-19 2007-12-19 Schering Corp Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
US8501997B2 (en) 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
KR20110128913A (ko) 2009-03-10 2011-11-30 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
RU2632659C2 (ru) * 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
WO2021011670A1 (en) * 2019-07-17 2021-01-21 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists and uses thereof
CN115160120B (zh) * 2022-08-02 2024-08-27 乐威医药（江苏）股份有限公司 一种多烷氧基芳香酮的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US785906A (en) * 1904-12-06 1905-03-28 Albert P Mcbride Casing packer and shoe for gas or oil wells.
MX16165A (es) * 1988-05-25 1994-02-28 Dow Chemical Co Alcoxi-1,2,4-triazolo[1,5-c]pirimidin-2-sulfonamidas, procedimiento para su preparacion e intermediarios.
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT1283839E (pt) * 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
WO2002062801A1 (en) * 2001-02-05 2002-08-15 Otsuka Pharmaceutical Factory, Inc. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
EP1622912B1 (en) 2009-05-27
KR20060005379A (ko) 2006-01-17
WO2004094431A2 (en) 2004-11-04
CA2522813C (en) 2009-09-08
PT1622912E (pt) 2009-08-17
TW201144317A (en) 2011-12-16
NO20055510D0 (no) 2005-11-22
PL1622912T3 (pl) 2009-11-30
DK1622912T3 (da) 2009-09-07
AU2004233334B2 (en) 2010-08-12
NZ542823A (en) 2009-03-31
CY1109263T1 (el) 2014-07-02
HK1085466A1 (en) 2006-08-25
AU2004233334A1 (en) 2004-11-04
US6897217B2 (en) 2005-05-24
ZA200508489B (en) 2007-04-25
NO332182B1 (no) 2012-07-23
IL171567A (en) 2013-01-31
TWI375677B (en) 2012-11-01
HRP20090394T1 (hr) 2009-08-31
CA2522813A1 (en) 2004-11-04
JP2006523619A (ja) 2006-10-19
MXPA05011366A (es) 2005-11-28
JP4527712B2 (ja) 2010-08-18
DE602004021250D1 (de) 2009-07-09
CN100503609C (zh) 2009-06-24
EP1622912A2 (en) 2006-02-08
WO2004094431A3 (en) 2004-12-02
MY139344A (en) 2009-09-30
BRPI0409787B1 (pt) 2018-08-21
CL2004000847A1 (es) 2005-03-11
US20040220194A1 (en) 2004-11-04
PE20050141A1 (es) 2005-04-01
ATE432282T1 (de) 2009-06-15
US20050222164A1 (en) 2005-10-06
TWI355381B (en) 2012-01-01
AR044041A1 (es) 2005-08-24
RU2005136166A (ru) 2006-06-10
RU2373210C2 (ru) 2009-11-20
NO20055510L (no) 2006-01-20
CN1777609A (zh) 2006-05-24
BRPI0409787A (pt) 2006-05-30
CO5700766A2 (es) 2006-11-30
SI1622912T1 (sl) 2009-10-31
JP2010059178A (ja) 2010-03-18
US7368449B2 (en) 2008-05-06
ECSP056115A (es) 2006-03-01
KR100831107B1 (ko) 2008-05-20
TW200427689A (en) 2004-12-16
PL378867A1 (pl) 2006-05-29
ES2326270T3 (es) 2009-10-06

Similar Documents

Publication Publication Date Title
IL178674A0 (en) PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
IL160878A0 (en) Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
PT1622912E (pt) Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina
ATE317844T1 (de) Adenosine a2a receptor antagonisten
DE60110219D1 (de) Adenosin a2a rezeptor antagonisten
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
TWI365879B (en) A2b adenosine receptor antagonists
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
IL178365A (en) Selective antagonists of a2a adenosine receptors
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
SMP200600024B (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
IL174771A0 (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
DK1678182T3 (da) Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
HK1118045A (en) 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
TH0401001406A (th) 2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a
ZA200608778B (en) Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
HK1062534A (en) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
PL378983A1 (pl) Pochodne ksantyny jako antagoniści receptora adenozyny A2B
HK1096086A (en) A2b adenosine receptor antagonists
HK1099015A (en) Selective antagonists of a2a adenosine receptors
PL383615A1 (pl) Arylindenopirydyny i arylindenopirymidyny oraz ich zastosowanie jako antagonistów receptora adenozynowego A2a
HK1094192A (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2719 DE 14-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.